Voyager Therapeutics, Inc. (VYGR) Operating Margin
- Operating margin · 12 months: Value -340.08%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -340.08% | Operating income / revenue. Period ending 2026-06-30. $-117.19M ÷ $34.46M × 100 ≈ -340.08% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -117.19M USD | Operating Income (Loss) |
| Revenue | 34.46M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 118.46M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-117.19M | $34.46M | (m) | $118.46M | (m) | -340.08% |
| 2026-03-31 | $-127.42M | $36.49M | (m) | $127.75M | (m) | -349.16% |
| 2025-12-31 | $-131.84M | $40.37M | (m) | $134.67M | (m) | -326.56% |
| 2025-09-30 | $-140.21M | $31.32M | (m) | $134.31M | (m) | -447.73% |
| 2025-06-30 | $-123.40M | $42.58M | (m) | $128.68M | (m) | -289.80% |
| 2025-03-31 | $-101.80M | $66.96M | (m) | $131.80M | (m) | -152.03% |
| 2024-12-31 | $-83.29M | $80.00M | (m) | $127.37M | (m) | -104.11% |
| 2024-09-30 | $9.07M | $64.28M | (m) | $117.54M | (m) | 14.12% |
| 2024-06-30 | $-6.65M | $44.26M | (m) | $113.16M | (m) | -15.03% |
| 2024-03-31 | $-17.05M | $19.54M | (m) | $100.70M | (m) | -87.29% |
| 2023-12-31 | $122.01M | $250.01M | (m) | $92.17M | (m) | 48.80% |
| 2023-09-30 | $43.39M | $158.40M | (m) | $80.97M | (m) | 27.39% |
| 2023-06-30 | $87.34M | $194.87M | (m) | $74.44M | (m) | 44.82% |
| 2023-03-31 | $93.40M | $190.73M | (m) | $64.98M | (m) | 48.97% |
| 2022-12-31 | $-50.84M | $40.91M | (m) | $60.76M | (m) | -124.27% |
| 2022-09-30 | $-20.57M | $70.53M | (m) | $60.23M | (m) | -29.17% |
| 2022-06-30 | $-60.16M | $30.93M | (m) | $58.81M | (m) | -194.52% |
| 2022-03-31 | $-69.38M | $31.57M | (m) | $65.79M | (m) | -219.75% |
| 2021-12-31 | $-73.62M | $37.41M | (m) | $73.79M | (m) | -196.76% |
| 2021-09-30 | $-103.05M | $15.88M | (m) | $81.76M | (m) | -648.96% |
| 2021-06-30 | $6.62M | $132.24M | (m) | $88.89M | (m) | 5.01% |
| 2021-03-31 | $26.23M | $159.56M | (m) | $98.81M | (m) | 16.44% |
| 2020-12-31 | $27.38M | $171.13M | (m) | $108.75M | (m) | 16.00% |
| 2020-09-30 | $37.34M | $197.26M | (m) | $123.31M | (m) | 18.93% |
| 2020-06-30 | $-64.99M | $99.86M | (m) | $128.05M | (m) | -65.08% |
| 2020-03-31 | $-46.82M | $117.26M | (m) | $127.20M | (m) | -39.93% |
| 2019-12-31 | $-51.68M | $104.39M | (m) | $119.73M | (m) | -49.51% |
| 2019-09-30 | $-61.07M | $73.72M | (m) | $100.10M | (m) | -82.84% |
| 2019-06-30 | $-64.41M | $55.39M | (m) | $86.95M | (m) | -116.29% |
| 2019-03-31 | $-99.30M | $11.87M | (m) | $74.88M | (m) | -836.24% |
| 2018-12-31 | $-91.09M | $7.62M | (m) | $64.91M | (m) | -1195.63% |
| 2018-09-30 | $-80.28M | $11.96M | (m) | $61.32M | (m) | -671.48% |
| 2018-06-30 | $-82.49M | $11.01M | (m) | $64.25M | (m) | -749.24% |
| 2018-03-31 | $-75.43M | $9.61M | (m) | $63.04M | (m) | -784.71% |
| 2017-12-31 | $-71.86M | $10.13M | (m) | $62.26M | (m) | -709.06% |
| 2017-09-30 | $-73.36M | $6.15M | (m) | $61.66M | (m) | -1192.41% |
| 2017-06-30 | $-60.37M | $8.31M | (m) | $52.41M | (m) | -726.35% |
| 2017-03-31 | $-51.35M | $10.85M | (m) | $47.59M | (m) | -473.13% |
| 2016-12-31 | $-41.30M | $14.22M | (m) | $42.25M | (m) | -290.43% |
| 2016-09-30 | $-34.90M | $16.80M | (m) | $38.75M | (m) | -207.78% |
| 2016-06-30 | $-28.54M | $18.42M | (m) | $34.92M | (m) | -154.93% |
| 2016-03-31 | $-22.89M | $19.59M | (m) | $30.89M | (m) | -116.87% |
| 2015-12-31 | $-20.25M | $17.33M | (m) | $27.68M | (m) | -116.85% |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $-16.95M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $-16.21M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-14.37M | (m) | (m) | $8.90M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |